Eris, Torrent Pharma, Natco, Lupin stand out in Rs157 billion India GLP-1 opportunity: Kotak
Eris Lifesciences, Torrent Pharma, Natco Pharma and Lupin are expected to see the highest contribution to FY2029E earnings per share from India's GLP-1 opportunity, at 4-12%, according to Kotak Institutional Equities. Sun Pharma is expected to generate the highest India Semaglutide sales among dome…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.